文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.

作者信息

Dilliard Sean A, Siegwart Daniel J

机构信息

Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX USA.

Department of Biomedical Engineering, The University of Texas Southwestern Medical Center, Dallas, TX USA.

出版信息

Nat Rev Mater. 2023;8(4):282-300. doi: 10.1038/s41578-022-00529-7. Epub 2023 Jan 19.


DOI:10.1038/s41578-022-00529-7
PMID:36691401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9850348/
Abstract

Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of medicines that directly reprogramme the central dogma of biology to prevent and treat disease. However, multiple biological barriers normally impede the intracellular delivery of nucleic acids, necessitating the use of a delivery system. Lipid and polymer nanoparticles represent leading approaches for the clinical translation of genetic drugs. These systems circumnavigate biological barriers and facilitate the intracellular delivery of nucleic acids in the correct cells of the target organ using passive, active and endogenous targeting mechanisms. In this Review, we highlight the constituent materials of these advanced nanoparticles, their nucleic acid cargoes and how they journey through the body. We discuss targeting principles for liver delivery, as it is the organ most successfully targeted by intravenously administered nanoparticles to date, followed by the expansion of these concepts to extrahepatic (non-liver) delivery. Ultimately, this Review connects emerging materials and biological insights playing key roles in targeting specific organs and cells in vivo.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/49e7ea566ebf/41578_2022_529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/bdd17506e13a/41578_2022_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/efdfa09949e9/41578_2022_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/49e7ea566ebf/41578_2022_529_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/bdd17506e13a/41578_2022_529_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/efdfa09949e9/41578_2022_529_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc2/9850348/49e7ea566ebf/41578_2022_529_Fig3_HTML.jpg

相似文献

[1]
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.

Nat Rev Mater. 2023

[2]
Nanoparticles for vaccine and gene therapy: Overcoming the barriers to nucleic acid delivery.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022-11

[3]
Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines.

Adv Drug Deliv Rev. 2022-9

[4]
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Eur J Pharm Biopharm. 2015-6

[5]
Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies.

J Funct Biomater. 2019-1-8

[6]
Selective organ targeting nanoparticles: from design to clinical translation.

Nanoscale Horiz. 2023-8-21

[7]
Lipid Nanoparticles for Cell-Specific in Vivo Targeted Delivery of Nucleic Acids.

Biol Pharm Bull. 2020

[8]
New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.

Pharmaceutics. 2021-12-1

[9]
Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines.

Cancers (Basel). 2021-12-6

[10]
mRNA nanodelivery systems: targeting strategies and administration routes.

Biomater Res. 2023-9-22

引用本文的文献

[1]
Peptide codes for organ-selective mRNA delivery.

Nat Mater. 2025-9-1

[2]
Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.

MedComm (2020). 2025-8-21

[3]
Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.

Mater Today Bio. 2025-8-8

[4]
Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation.

Front Drug Deliv. 2024-4-26

[5]
Towards the elimination of infectious HPV: exploiting CRISPR/Cas innovations.

Front Cell Infect Microbiol. 2025-8-4

[6]
Bioengineered microneedles and nanomedicine as therapeutic platform for tissue regeneration.

J Nanobiotechnology. 2025-8-19

[7]
In Silico discovery of novel androgen receptor inhibitors for prostate cancer therapy using virtual screening, molecular docking, and molecular dynamics simulations.

Sci Rep. 2025-8-11

[8]
Nanotechnology-based mRNA vaccines.

Nat Rev Methods Primers. 2023

[9]
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics.

Pharmaceutics. 2025-7-12

[10]
Precision nanomaterials in colorectal cancer: advancing photodynamic and photothermal therapy.

RSC Adv. 2025-7-25

本文引用的文献

[1]
Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis.

Proc Natl Acad Sci U S A. 2022-2-22

[2]
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles.

Nat Nanotechnol. 2022-3

[3]
CAR T cells produced in vivo to treat cardiac injury.

Science. 2022-1-7

[4]
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles.

Proc Natl Acad Sci U S A. 2021-12-28

[5]
Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes.

J Am Chem Soc. 2021-12-22

[6]
Lipid nanoparticles for mRNA delivery.

Nat Rev Mater. 2021

[7]
Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles.

J Control Release. 2021-9-10

[8]
Lipids and Lipid Derivatives for RNA Delivery.

Chem Rev. 2021-10-27

[9]
Liposome composition in drug delivery design, synthesis, characterization, and clinical application.

Adv Drug Deliv Rev. 2021-9

[10]
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

N Engl J Med. 2021-8-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索